Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC Meeting Abstract
| Authors: | Bardia, A.; Diamond, J. R.; Mayer, I. A.; Starodub, A. N.; Moroose, R. L.; Isakoff, S. J.; Ocean, A. J.; Guarino, M. J.; Berlin, J. D.; Messersmith, W. A.; Thomas, S. S.; O'Shaughnessy, J. A.; Kalinsky, K.; Maurer, M.; Chang, J. C.; Forero, A.; Traina, T.; Gucalp, A.; Wilhelm, F.; Wegener, W. A.; Maliakal, P.; Sharkey, R. M.; Goldenberg, D. M.; Vahdat, L. T. |
| Abstract Title: | Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC |
| Meeting Title: | 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 76 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2015 Dec 8-12 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-02-15 |
| Language: | English |
| ACCESSION: | WOS:000375622402143 |
| DOI: | 10.1158/1538-7445.sabcs15-pd3-06 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PD3-06 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
